Research Studies Currently Recruiting

ALTO

ALTO-207-201 is a phase 2b clinical research trial.  Participants must have been previously diagnosed with Major Depressive Disorder (MDD), and need to have tried two to five antidepressant treatments with minimal improvement in their depression symptoms.

The purpose of this research study is to compare the effectiveness of the study drug in treating symptoms of depression when combined with a traditional anti-depressant medication.  In addition, this trial aims to evaluate study drug safety, measure how the study drug moves through the body over time and understand the brain activity patterns, thinking and behavior that can be seen in participants with treatment resistant depression prior to and while taking the study drug. The research study will take up to 17 weeks and require onsite visits in Worcester, MA.

More information regarding the trial can be found here: https://clinicaltrials.gov/study/NCT07553637  If you are interested in pursuing this trial please contact Patricia Arruda, RN Clinical Trial Manager at 508-425-6189 or patricia.arruda@reliantmedicalgroup.org

Cadence

Cadence is an observational registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS).  The primary goal is to better understand patient and clinical characteristics, complications, long-term clinical and patient-reported outcomes associated with the different CAD and CAS treatments and health-resource utilization.  More information can be found here: https://clinicaltrials.gov/study/NCT05791708?term=NCT05791708&rank=1

CodeBreaK

CodeBreaK 202 is a interventional study for patients with non-small cell lung cancers with Stage IV or Advanced Stage IIIB/C disease.  The primary goal is to compare the survival rate after treatment with either Sotorasib Platinum Doublet Combination or Pembrolizumab Platinum Doublet Therapy.  More information can be found here: https://clinicaltrials.gov/study/NCT05920356?term=NCT05920356&rank=1

SUNRAY

SUNRY-02 is a phase 3 clinical drug trial.  The purpose of this study is to learn more about olomorasib, a possible new treatment for lung cancer.  The study aims to learn whether it can prevent cancer from returning for a longer period of time, whether it works better than a placebo (a pretend drug) and what are the possible side effects.  Patients enrolled in this study will be randomized to take either olomorasib or a placebo drug in addition to standard treatments.  More information can be found here: https://clinicaltrials.gov/study/NCT06890598.